Document is current
Any future updates will be listed below
-
Authors
Ahmad, Maud
Hegele, Robert A. https://orcid.org/0000-0003-2861-5325
-
Funding
Funding for this research was provided by:
Canadian Institutes of Health Research (Foundation Award)
Heart and Stroke Foundation of Canada (G-21-0031455)
Academic Medical Organization of Southwestern Ontario (INN21-011)
- License Information
-
More Information
Article History
Accepted: 15 December 2024
First Online: 28 January 2025
Declarations
:
: Robert A. Hegele is supported by the Jacob J. Wolfe Distinguished Medical Research Chair, the Edith Schulich Vinet Research Chair, and the Martha G. Blackburn Chair in Cardiovascular Research. Robert A. Hegele holds operating grants from the Canadian Institutes of Health Research (Foundation award), the Heart and Stroke Foundation of Ontario (G-21-0031455), and the Academic Medical Association of Southwestern Ontario (INN21-011).
: Maud Ahmad has no conflicts of interest that are directly relevant to the content of this article. Robert A. Hegele reports consulting fees from Acasti, Aegerion, Akcea/Ionis, Amgen, Arrowhead, Boston Heart, HLS Therapeutics, Pfizer, Medison, Novartis, Regeneron, Sanofi, and Ultragenyx. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the article apart from those disclosed.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Both authors designed the approach to the literature review, drafted the article, made revisions, and approved the final version.
